- ￥1070 - 3770
- Solarbio
- 北京
- IP5930
- 2025年12月22日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
PF-04991532
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
1215197-37-7
- 规格：
25mg/5mg/10mg
| 规格： | 25mg | 产品价格： | ￥3770.0 |
|---|---|---|---|
| 规格： | 5mg | 产品价格： | ￥1070.0 |
| 规格： | 10mg | 产品价格： | ￥1880.0 |
| 基本信息 | |
| CAS | No.1215197-37-7 |
| 英文名称 | PF-04991532 |
| 分子式 | C18H19F3N4O3 |
| 分子量 | 396.36 |
| 溶解性 | Soluble in DMSO |
| 纯度 | ≥98% |
| 外观(性状) | White to off-white Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| SMILES | C1CCC(C1)C[C@@H](C(=O)NC2=NC=C(C=C2)C(=O)O)N3C=C(N=C3)C(F)(F)F |
| InChIKey | GKMLFBRLRVQVJO-ZDUSSCGKSA-N |
| InChI | InChI=1S/C18H19F3N4O3/c19-18(20，21)14-9-25(10-23-14)13(7-11-3-1-2-4-11)16(26)24-15-6-5-12(8-22-15)17(27)28/h5-6，8-11，13H，1-4，7H2，(H，27，28)(H，22，24，26)/t13-/m0/s1 |
| PubChem CID | 46181428 |
| 靶点 | Glucokinase |
| 通路 | Metabolic Enzyme&Protease |
| 背景说明 | PF-04991532 是一种有效的肝选择性葡萄糖激酶激活剂。 |
| 生物活性 | PF-04991532 is a potent， hepatoselective glucokinase activator with EC50s of 80 and 100 nM in human and rat， respectively.[1] |
| IC50 | EC50: 80 nM (glucokinase in human)， 100 nM (glucokinase in rat)[1] |
| In Vitro | PF-04991532 is a potent， hepatoselective glucokinase activator with EC50s of 80 nM in human and 100 nM in rat and also a Phase 2 clinical candidate. Mechanistic experiments conducted in freshly isolated primary rat hepatocytes treated for 1 hour with PF-04991532 show increased 2-[14C]-deoxyglucose uptake (EC50?=1.261 μM) and increased glucose oxidation (EC50=5.769 μM). Additionally， PF-04991532 decreases the production of glucose from 1-[14C]-lactate in a dose dependent manner (EC50?=0.626 μM). In isolated rat hepatocytes， PF-04991532 increases the expression of G6Pase compare to cells treated only with 100 nM glucagon， and the greatest increase in G6Pase mRNA expression is in the presence of 25 mM glucose， 100 nM glucagon and PF-04991532[1]. |
| 细胞实验 | A single dose of PF-04991532 increases the glucose infusion rate in order to maintain hyperglycemia. Despite the elevations in plasma triglycerides， surprisingly， hepatic triglycerides in rats dosed with 19 days of PF-04991532 are identical to vehicle treated GK rats. In an additional cohort treated for 28 days， identical hepatic lipid concentrations are observed between vehicle and rats dosed with PF-04991532 (Vehicle: 9.89±0.31; PF-04991532 100 mg/kg: 9.91±0.31). In rats treated with PF-04991532， there is increased expression of lipogenic gene expression such as acetyl-CoA carboxylase (ACC)， ATP citrate lyase (ACLY)， and fatty acid synthase (FAS)[1]. |
| 细胞实验 | Primary rat hepatocytes are used to determine the expression of G6Pase. 50，000 freshly isolated rat hepatocytes are incubated in Williams E media overnight supplemented with 100 nM dexamethasone， 1×ITS， and 1×PenStrep. The following morning the media is aspirated， and changed to DMEM no glucose media supplemented with either 5 mM glucose， 25 mM glucose， 1 μM insulin， 100 nM glucagon， or 10 μM PF-04991532. Following 2 hours the media is aspirated， washed twice， and 100 μL of RLT is added to the cells. RNA is extracted with a RNeasy kit[1]. |
| 动物实验 | 13 week old male Goto Kakizaki rats with in-dwelling carotid artery and jugular vein catheters are used in this study. Surgeries are performed one day before shipping. Upon arrival， animals are individually housed， allowed ad libitum chow， and acclimated to their new environment for 6 to 7 days. Animals are randomly assigned either a 100 mg/kg PF-04991532 treatment or vehicle control treatment and orally gavaged at 5 mL/kg. On the day of the experiment， 0.5% Methyl cellulose vehicle is used in vehicle-treated rats. Studies are performed in unstressed， awake， chronically catheterized rats using the insulin clamp technique， in combination with [3-3H] glucose. At the end of the in vivo studies， rats are euthanized[1]. |
| 数据来源文献 | [1]. Erion DM， et al. The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One. 2014 May 23;9(5):e97139. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验或者互作蛋白复合物（红色+黄色）洗脱 Step 5：分析检测—Western Blot 或者质谱 常用“黑话” 以上示例图证明了 EDR1 和 EDR4 有相互作用。如果想要设计好实验，先清楚以下常用“黑话”含义。 阳性对照：证实细胞裂解物中确实存在靶蛋白（IP）或者互作蛋白对（co-IP，比如诱饵蛋白X和靶蛋白 Y），即为常说的 input。可直接取抽好的蛋白溶液进行 Western。 阴性对照：用来排除假阳性。IP/co-IP 后靶蛋白或者互作蛋白对都检测到了，固然是值得高兴
一、原理：免疫共沉淀（Co-Immunoprecipitation）是以抗体和抗原之间的专一性作用为基础的用于研究蛋白质相互作用的经典方法。是确定两种蛋白质在完整细胞内生理性相互作用的有效方法。其原理是：当细胞在非变性条件下被裂解时，完整细胞内存在的许多蛋白质－蛋白质间的相互作用被保留了下来。如果用蛋白质X的抗体免疫沉淀X，那么与X在体内结合的蛋白质Y也能沉淀下来。目前多用精制的prorein A预先结合固化在argarose的beads上，使之与含有抗原的溶液及抗体反应后，beads
_ChIP_method.html Chromatin IP Method, ChIP buffers, Notes on ChIP Method, Quantative PCR using 32P dCTP. Hahn Lab. ChIP Assay Protocol PDF - /attach/2008/2008-02-01/2B/2B6C4EA25F257424710A50E83CB2F380.pdf Formaldehyde cross-linking
技术资料暂无技术资料 索取技术资料
